Tai A - Search Results

1

Fluorescent retinoid X receptor ligands for fluorescence polarization assay.

Yamada S, Ohsawa F, Fujii S, Shinozaki R, Makishima M, Naitou H, Enomoto S, Tai A, Kakuta H. Yamada S, et al. Among authors: tai a. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5143-6. doi: 10.1016/j.bmcl.2010.07.011. Epub 2010 Jul 8. Bioorg Med Chem Lett. 2010. PMID: 20667726

2

Replacing alkyl sulfonamide with aromatic sulfonamide in sulfonamide-type RXR agonists favors switch towards antagonist activity.

Morishita K, Yakushiji N, Ohsawa F, Takamatsu K, Matsuura N, Makishima M, Kawahata M, Yamaguchi K, Tai A, Sasaki K, Kakuta H. Morishita K, et al. Among authors: tai a. Bioorg Med Chem Lett. 2009 Feb 1;19(3):1001-3. doi: 10.1016/j.bmcl.2008.11.086. Epub 2008 Nov 27. Bioorg Med Chem Lett. 2009. PMID: 19095448

3

Modification at the acidic domain of RXR agonists has little effect on permissive RXR-heterodimer activation.

Fujii S, Ohsawa F, Yamada S, Shinozaki R, Fukai R, Makishima M, Enomoto S, Tai A, Kakuta H. Fujii S, et al. Among authors: tai a. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5139-42. doi: 10.1016/j.bmcl.2010.07.012. Epub 2010 Jul 8. Bioorg Med Chem Lett. 2010. PMID: 20656484

4

Feasibility of structural modification of retinoid X receptor agonists to separate blood glucose-lowering action from adverse effects: studies in KKA(y) type 2 diabetes model mice.

Kakuta H, Ohsawa F, Yamada S, Makishima M, Tai A, Yasui H, Yoshikawa Y. Kakuta H, et al. Among authors: tai a. Biol Pharm Bull. 2012;35(4):629-33. doi: 10.1248/bpb.35.629. Biol Pharm Bull. 2012. PMID: 22466572 Free article.

5

Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency.

Ohsawa F, Yamada S, Yakushiji N, Shinozaki R, Nakayama M, Kawata K, Hagaya M, Kobayashi T, Kohara K, Furusawa Y, Fujiwara C, Ohta Y, Makishima M, Naitou H, Tai A, Yoshikawa Y, Yasui H, Kakuta H. Ohsawa F, et al. Among authors: tai a. J Med Chem. 2013 Mar 14;56(5):1865-77. doi: 10.1021/jm400033f. Epub 2013 Feb 20. J Med Chem. 2013. PMID: 23391145

6

RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.

Kakuta H, Yakushiji N, Shinozaki R, Ohsawa F, Yamada S, Ohta Y, Kawata K, Nakayama M, Hagaya M, Fujiwara C, Makishima M, Uno S, Tai A, Maehara A, Nakayama M, Oohashi T, Yasui H, Yoshikawa Y. Kakuta H, et al. Among authors: tai a. ACS Med Chem Lett. 2012 Apr 9;3(5):427-32. doi: 10.1021/ml300055n. eCollection 2012 May 10. ACS Med Chem Lett. 2012. PMID: 24900488 Free PMC article.

7

RXR partial agonist produced by side chain repositioning of alkoxy RXR full agonist retains antitype 2 diabetes activity without the adverse effects.

Kawata K, Morishita K, Nakayama M, Yamada S, Kobayashi T, Furusawa Y, Arimoto-Kobayashi S, Oohashi T, Makishima M, Naitou H, Ishitsubo E, Tokiwa H, Tai A, Kakuta H. Kawata K, et al. Among authors: tai a. J Med Chem. 2015 Jan 22;58(2):912-26. doi: 10.1021/jm501863r. Epub 2014 Dec 17. J Med Chem. 2015. PMID: 25486327

8

Analgesic agents without gastric damage: design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors.

Zheng X, Oda H, Takamatsu K, Sugimoto Y, Tai A, Akaho E, Ali HI, Oshiki T, Kakuta H, Sasaki K. Zheng X, et al. Among authors: tai a. Bioorg Med Chem. 2007 Jan 15;15(2):1014-21. doi: 10.1016/j.bmc.2006.10.029. Epub 2006 Oct 18. Bioorg Med Chem. 2007. PMID: 17079150

9

Reduction of lipophilicity at the lipophilic domain of RXR agonists enables production of subtype preference: RXRalpha-preferential agonist possessing a sulfonamide moiety.

Takamatsu K, Takano A, Yakushiji N, Morishita K, Matsuura N, Makishima M, Ali HI, Akaho E, Tai A, Sasaki K, Kakuta H. Takamatsu K, et al. Among authors: tai a. ChemMedChem. 2008 Mar;3(3):454-60. doi: 10.1002/cmdc.200700265. ChemMedChem. 2008. PMID: 18157857

10

The first potent subtype-selective retinoid X receptor (RXR) agonist possessing a 3-isopropoxy-4-isopropylphenylamino moiety, NEt-3IP (RXRalpha/beta-dual agonist).

Takamatsu K, Takano A, Yakushiji N, Morohashi K, Morishita K, Matsuura N, Makishima M, Tai A, Sasaki K, Kakuta H. Takamatsu K, et al. Among authors: tai a. ChemMedChem. 2008 May;3(5):780-7. doi: 10.1002/cmdc.200700313. ChemMedChem. 2008. PMID: 18297677

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

611 results

Search Page